指南与共识流行病学与生物统计基础与转化研究

美国预防服务工作组结直肠癌筛查推荐声明

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.
指南 / 共识 · JAMA · 2021-01-01

美国预防服务工作组(USPSTF)更新2016年推荐,基于系统综述和模拟模型,评估40岁及以上成人结直肠癌筛查的获益与风险。推荐50-75岁全部筛查(A级),45-49岁筛查(B级),76-85岁选择性提供(C级)。

要点

  • 50-75岁成人均推荐筛查(A级推荐)
  • 45-49岁成人推荐筛查(B级推荐)
  • 76-85岁曾筛查者选择性提供筛查(C级推荐)

核心结论

  • USPSTF以高确定性认为50-75岁筛查净获益显著,以中等确定性认为45-49岁筛查净获益中等,76-85岁曾筛查者净获益小。

研究设计与样本

  • USPSTF委托系统综述评估40岁及以上成人筛查的获益与风险,并委托癌症干预与监测建模网络提供比较建模信息。

主要发现

  • 结直肠癌是男女性第三大癌症死因,2021年美国预计52 980人死于该病。
  • 40-49岁成人结直肠癌(特别是腺癌)发病率从2000-2002年至2014-2016年增加近15%。
  • 2016年美国26%合格成人从未筛查,2018年31%筛查未达最新标准。

关键数值与推荐

  • 50-75岁全部成人推荐筛查(A级推荐)。
  • 45-49岁成人推荐筛查(B级推荐)。
  • 76-85岁曾筛查者选择性提供筛查(C级推荐),需考虑整体健康、既往筛查史和偏好。

临床怎么用

  • 对50-75岁成人普遍推荐筛查,45-49岁开始筛查,76-85岁根据个体情况选择性提供。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15% from 2000-2002 to 2014-2016. In 2016, 26% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31% were not up to date with screening. OBJECTIVE: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal Cancer Working Group to provide information from comparative modeling on how estimated life-years gained, colorectal cancer cases averted, and colorectal cancer deaths averted vary by different starting and stopping ages for various screening strategies. POPULATION: Asymptomatic adults 45 years or older at average risk of colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]). EVIDENCE ASSESSMENT: The USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened has small net benefit. Adults who have never been screened for colorectal cancer are more likely to benefit. RECOMMENDATION: The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient's overall health, prior screening history, and preferences. (C recommendation).

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Davidson KW, Barry MJ, Mangione CM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021. PMID: 34003218. doi:10.1001/jama.2021.6238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。